Species |
Cynomolgus/Rhesus macaque |
Protein Construction |
PD-L1/B7-H1 (Phe19-Arg238) Accession # G7PSE7 |
His |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized PD-L1/B7-H1, His, Cynomolgus/Rhesus macaque at 1μg/ml (100μl/Well) on the plate can bind AntiPDL1 Antibody, hFc Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
26 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Target Background |
B7-H1, also known as PD-L1 and CD274, is an approximately 65 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules. PD-L1 has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. |
Synonyms |
CD274; PDL1; PD-L1; PD-L1B7 homolog 1;B7-H; B7H1; B7-H1; PDCD1L1; PDCD1LG1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.